Global Cardio Oncology Registry

Summary

Objectives

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational,
multicenter prospective observational cohort registry, with the goal of collecting
clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk
factors associated with increased incidence of cancer therapy related cardiovascular
toxicity (CTR-CVT) in different settings and to derive and validate risk scores for
cardio oncology patients treated in different geographic locations throughout the world.

G-COR will involve the collaboration from 124 hospitals from 24 countries that completed
survey with sites demographics. It will evaluate cardiovascular disease in three distinct
populations of cancer patients (hematological malignancies: lymphomas, leukemias,
multiple myeloma; breast cancer patients; and patients treated with check point
inhibitors immunotherapy).

G-COR will evaluate the cardiovascular impact of different cancer treatments in the
above-described patients, and similarities and differences in diagnostic and treatment
modalities as well as outcomes and the impact of socioeconomic factors and risk factors
for toxicities in a large worldwide population.

G-COR will study the impact of cancer in CV disease in cancer patients treated at
academic centers as well as in patients treated at community hospitals, through a
systematic prospective data collection in a global digital platform.

G-COR is an IRB approved prospective registry, conducted with the logistical support of
C5 Clinical Research Division and the Cardiovascular Outcomes Registries and Research
(CORR) group at the Cleveland Clinic and have developed eCRFs with an extensive Red Cap
Cloud platform.

G-COR Executive, Scientific and topic committees are led by North American, European,
Latin American, Australian and Asian representatives from both academic and community
centers.

The pilot phase of G-COR enrolls breast cancer patients only, and the global phase will
include all three cohorts of patients (breast, Hem and ICIs).

The investigators have started enrolling patients for G-COR pilot phase with US centers,
and will start the global international phase in 2023.